- Home
- CARV vs IMRN Comparison
CARV vs IMRN Comparison
Compare CARV & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- IMRN
- Stock Information
- Founded
- CARV 1948
- IMRN 1994
- Country
- CARV United States
- IMRN Australia
- Employees
- CARV N/A
- IMRN N/A
- Industry
- CARV Savings Institutions
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- IMRN Health Care
- Exchange
- CARV Nasdaq
- IMRN Nasdaq
- Market Cap
- CARV 9.6M
- IMRN 9.2M
- IPO Year
- CARV 1994
- IMRN N/A
- Fundamental
- Price
- CARV $2.35
- IMRN $1.83
- Analyst Decision
- CARV
- IMRN Strong Buy
- Analyst Count
- CARV 0
- IMRN 1
- Target Price
- CARV N/A
- IMRN $5.00
- AVG Volume (30 Days)
- CARV 40.8K
- IMRN 53.2K
- Earning Date
- CARV 08-13-2025
- IMRN 08-29-2025
- Dividend Yield
- CARV N/A
- IMRN N/A
- EPS Growth
- CARV N/A
- IMRN N/A
- EPS
- CARV N/A
- IMRN N/A
- Revenue
- CARV $22,032,000.00
- IMRN $4,777,422.00
- Revenue This Year
- CARV N/A
- IMRN N/A
- Revenue Next Year
- CARV N/A
- IMRN N/A
- P/E Ratio
- CARV N/A
- IMRN N/A
- Revenue Growth
- CARV N/A
- IMRN 48.63
- 52 Week Low
- CARV $1.30
- IMRN $1.50
- 52 Week High
- CARV $3.20
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- CARV 68.97
- IMRN 55.42
- Support Level
- CARV $1.61
- IMRN $1.73
- Resistance Level
- CARV $2.56
- IMRN $1.85
- Average True Range (ATR)
- CARV 0.17
- IMRN 0.11
- MACD
- CARV 0.06
- IMRN 0.01
- Stochastic Oscillator
- CARV 77.89
- IMRN 66.13
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.